Marizyme Past Earnings Performance
Past criteria checks 0/6
Marizyme's earnings have been declining at an average annual rate of -73.1%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 50.1% per year.
Key information
-73.1%
Earnings growth rate
-51.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 50.1% |
| Return on equity | n/a |
| Net Margin | -13,393.8% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Marizyme makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 1 | -79 | 11 | 2 |
| 30 Jun 23 | 0 | -48 | 8 | 3 |
| 31 Mar 23 | 0 | -35 | 7 | 3 |
| 31 Dec 22 | 0 | -38 | 8 | 4 |
| 30 Sep 22 | 0 | -20 | 9 | 4 |
| 30 Jun 22 | 0 | -20 | 9 | 4 |
| 31 Mar 22 | 0 | -14 | 8 | 3 |
| 31 Dec 21 | 0 | -11 | 7 | 2 |
| 30 Sep 21 | 0 | -8 | 7 | 2 |
| 30 Jun 21 | 0 | -9 | 8 | 1 |
| 31 Mar 21 | 0 | -8 | 6 | 1 |
| 31 Dec 20 | 0 | -6 | 5 | 1 |
| 30 Sep 20 | 0 | -3 | 3 | 0 |
| 30 Jun 20 | 0 | -2 | 2 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | 0 | 0 | 0 |
| 31 Mar 19 | 0 | 0 | 0 | 0 |
| 31 Dec 18 | 0 | 0 | 0 | 0 |
| 30 Sep 18 | 0 | -1 | 0 | 0 |
| 30 Jun 18 | 0 | -1 | 0 | 0 |
| 31 Mar 18 | 0 | -1 | 0 | 0 |
| 31 Dec 17 | 0 | -1 | 0 | 0 |
| 31 Dec 16 | 0 | -1 | 0 | 0 |
| 31 Dec 15 | 0 | -9 | 1 | 0 |
| 31 Dec 14 | 0 | -10 | 1 | 0 |
| 31 Dec 13 | 0 | -2 | 2 | 0 |
| 30 Sep 13 | 23 | -6 | 16 | 0 |
| 30 Jun 13 | 23 | -2 | 20 | 0 |
Quality Earnings: MRZM is currently unprofitable.
Growing Profit Margin: MRZM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MRZM is unprofitable, and losses have increased over the past 5 years at a rate of 73.1% per year.
Accelerating Growth: Unable to compare MRZM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRZM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: MRZM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.